Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-07 20:41 | 2026-07-06 | GLUE | Monte Rosa Therapeutics, Inc. | Townson Sharon | Officer | OPT+S | $23.31 | 6,000 | $139,849 | 67,845 |
| 2026-07-06 20:30 | 2026-07-01 | SRRK | Scholar Rock Holding Corp | FLIER JEFFREY S. | Director | SELL | $53.88 | 3,053 | $164,490 | 27,856 |
| 2026-07-06 20:30 | 2026-07-01 | SRRK | Scholar Rock Holding Corp | Reed Joshua | Director | SELL | $53.74 | 3,053 | $164,067 | 19,518 |
| 2026-07-06 20:30 | 2026-07-01 | SRRK | Scholar Rock Holding Corp | Peng Katie | Director | SELL | $53.88 | 5,446 | $293,404 | 34,301 |
| 2026-07-06 20:51 | 2026-07-02 | RGNX | REGENXBIO Inc. | PAKOLA STEVE | Officer | OPT+S | $13.64 | 2,161 | $29,476 | 213,009 |
| 2026-07-06 20:30 | 2026-07-01 | SRRK | Scholar Rock Holding Corp | Burow Kristina | Director | SELL | $53.74 | 3,053 | $164,064 | 114,657 |
| 2026-07-06 20:30 | 2026-07-01 | SRRK | Scholar Rock Holding Corp | Gilman Michael | Director | SELL | $53.88 | 2,544 | $137,058 | 59,511 |
| 2026-07-07 00:25 | 2026-07-01 | IBRX | ImmunityBio, Inc. | Selecky Christobel | Director | OPT+S | $9.02 | 159,478 | $1,439,066 | 0 |
| 2026-07-07 00:26 | 2026-07-02 | IBRX | ImmunityBio, Inc. | Cohen Cheryl | Director | OPT+S | $9.50 | 131,210 | $1,246,941 | 125,386 |
| 2026-07-06 23:48 | 2026-07-01 | PALI | PALISADE BIO, INC. | Baltera Robert Jr. | Director | BUY | $1.98 | 30,000 | $59,400 | 366,904 |
| 2026-07-06 23:31 | 2026-07-06 | PCVX | Vaxcyte, Inc. | GUGGENHIME ANDREW | Officer | OPT+S | $57.28 | 10,000 | $572,837 | 104,395 |
| 2026-07-06 23:15 | 2026-07-01 | ADPT | Adaptive Biotechnologies Corp | BOBULSKY SUSAN | Officer | SELL | $22.00 | 487 | $10,714 | 406,288 |
| 2026-07-06 23:19 | 2026-07-01 | ADPT | Adaptive Biotechnologies Corp | LO FRANCIS | Officer | OPT+S | $22.51 | 95,842 | $2,157,681 | 230,713 |
| 2026-07-06 22:25 | 2026-07-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | Officer | OPT+S | $56.33 | 2,250 | $126,736 | 156,760 |
| 2026-07-06 21:01 | 2026-07-02 | IMVT | Immunovant, Inc. | Venker Eric | Director, Officer | OPT+S | $38.48 | 3,092 | $118,980 | 254,280 |
| 2026-07-06 10:30 | 2024-06-06 | DYAI | DYADIC INTERNATIONAL INC | Francisco Trust under agreement dated February 28, 1996 | 10% owner | SELL | $1.99 | 172,864 | $343,757 | 3,375,664 |
| 2026-07-02 20:29 | 2026-07-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer | OPT+S | $29.90 | 14,609 | $436,865 | 0 |
| 2026-07-02 20:12 | 2026-06-30 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | Officer | SELL | $19.09 | 50,000 | $954,500 | 225,857 |
| 2026-07-02 20:28 | 2026-07-01 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | Director, Officer | SELL | $29.98 | 34,501 | $1,034,254 | 287,171 |
| 2026-07-02 20:07 | 2026-06-30 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Officer | OPT+S | $14.00 | 6,566 | $91,924 | 8,617 |
| 2026-07-02 20:14 | 2026-07-01 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer | SELL | $126.29 | 15,000 | $1,894,400 | 607,133 |
| 2026-07-02 20:05 | 2026-07-01 | FENC | FENNEC PHARMACEUTICALS INC. | Raykov Rosty | OPT+S | $10.41 | 9,599 | $99,926 | 138,855 | |
| 2026-07-02 20:42 | 2026-07-01 | HALO | HALOZYME THERAPEUTICS, INC. | Connaughton Bernadette | Director | SELL | $76.71 | 1,625 | $124,651 | 42,044 |
| 2026-07-03 00:13 | 2026-07-01 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Officer | OPT+S | $132.74 | 5,500 | $730,070 | 177,873 |
| 2026-07-02 22:30 | 2026-07-01 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | Director, Officer | OPT+S | $115.29 | 80,000 | $9,223,528 | 666,568 |
| 2026-07-02 22:30 | 2026-07-01 | KYMR | Kymera Therapeutics, Inc. | Goodman Noah | Officer | SELL | $114.29 | 3,389 | $387,329 | 47,179 |
| 2026-07-02 22:30 | 2026-06-30 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | Officer | OPT+S | $114.96 | 77,109 | $8,864,828 | 244,883 |
| 2026-07-02 21:39 | 2026-06-29 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Director | SELL | $108.05 | 76,650 | $8,281,902 | 462,856 |
| 2026-07-02 20:05 | 2026-06-30 | BEAM | Beam Therapeutics Inc. | Simon Amy | Officer | SELL | $34.73 | 373 | $12,954 | 102,363 |
| 2026-07-01 20:22 | 2026-06-29 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | Officer | SELL | $10.02 | 7,000 | $70,151 | 83,865 |
| 2026-07-01 20:22 | 2026-06-29 | CADL | Candel Therapeutics, Inc. | Barone Francesca | Officer | SELL | $10.06 | 23,447 | $235,769 | 77,362 |
| 2026-07-01 20:10 | 2026-06-29 | TARA | Protara Therapeutics, Inc. | Shefferman Jesse | Director, Officer | OPT+S | $4.09 | 215,687 | $882,160 | 721,832 |
| 2026-07-01 20:23 | 2026-06-30 | XFOR | X4 Pharmaceuticals, Inc | KIRSKE DAVID | Officer | SELL | $4.26 | 8,543 | $36,428 | 167,750 |
| 2026-07-02 00:08 | 2026-06-29 | RGNX | REGENXBIO Inc. | PAKOLA STEVE | Officer | OPT+S | $12.23 | 56,333 | $688,755 | 213,009 |
| 2026-07-01 22:47 | 2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | Director, Officer | SELL | $4.48 | 25,947 | $116,243 | 377,817 |
| 2026-07-01 22:48 | 2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | Bhalla Narinder Pal | Officer | SELL | $4.42 | 22,306 | $98,593 | 82,194 |
| 2026-07-01 22:49 | 2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | Officer | SELL | $4.48 | 4,666 | $20,904 | 137,482 |
| 2026-07-01 22:49 | 2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | Tamayo Louis Edward | Officer | SELL | $4.49 | 4,641 | $20,838 | 97,024 |
| 2026-07-01 22:25 | 2026-06-29 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Director | OPT+S | $187.99 | 5,580 | $1,048,967 | 21,656 |
| 2026-07-01 21:19 | 2026-06-30 | TECX | Tectonic Therapeutic, Inc. | McNamara Peter | Officer | OPT+S | $35.00 | 172 | $6,020 | 55,285 |
| 2026-07-01 20:57 | 2026-06-30 | GLUE | Monte Rosa Therapeutics, Inc. | Janku Filip | Officer | OPT+S | $24.50 | 5,407 | $132,472 | 60,612 |
| 2026-07-01 21:04 | 2026-06-29 | IBRX | ImmunityBio, Inc. | Selecky Christobel | Director | OPT+S | $9.01 | 96,722 | $871,214 | 0 |
| 2026-07-01 20:17 | 2026-06-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | Officer | OPT+S | $28.02 | 7,500 | $210,150 | 26,250 |
| 2026-07-01 20:05 | 2026-06-29 | BEAM | Beam Therapeutics Inc. | Evans John M. | Director, Officer | OPT+S | $34.90 | 50,000 | $1,745,035 | 1,047,205 |
| 2026-06-30 20:05 | 2026-06-26 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer | OPT+S | $44.90 | 2,732 | $122,667 | 886 |
| 2026-06-30 20:05 | 2026-06-26 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | Officer | SELL | $44.75 | 5,000 | $223,750 | 16,009 |
| 2026-06-30 20:05 | 2026-06-29 | GLUE | Monte Rosa Therapeutics, Inc. | Janku Filip | Officer | OPT+S | $22.95 | 6,000 | $137,700 | 59,992 |
| 2026-06-30 20:05 | 2026-06-26 | VCEL | Vericel Corp | Flynn Sean C. | Officer | OPT+S | $45.64 | 15,000 | $684,600 | 1,647 |
| 2026-06-30 20:05 | 2026-06-29 | GLUE | Monte Rosa Therapeutics, Inc. | Manning Anthony M. | Director | OPT+S | $23.11 | 10,000 | $231,100 | 0 |
| 2026-06-30 20:05 | 2026-06-26 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer | OPT+S | $45.00 | 10,000 | $450,000 | 75,753 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.